Pfizer-BioNTech COVID-19 vaccine could potentially be available by December.
Pfizer and BioNTech could secure emergency US Food and Drug Administration and European authorization for their COVID-19 vaccine in December after final trial results showed a 95% success rate in treating the virus with no serious side effects.
The vaccine’s efficacy was found to be consistent across different groups of people. In its clinical trials, 170 volunteers with COVID-19 in Pfizer’s trial involving more than 43,000 people, 162 had received a placebo and not the vaccine, meaning the vaccine was 95% effective. Of the 10 people who had severe COVID-19, one had received the vaccine.
Pfizer said it expects to make as many as 50 million vaccine doses in 2020, enough to protect 25 million people and then produce up to 1.3 billion doses in the following year.
AstraZeneca’s COVID-19 vaccine candidate shows promising results in the elderly group.
AstraZeneca and Oxford University recently revealed that its COVID-19 vaccine candidate showed a strong immune response in older adults.
The data, published in The Lancet medical journal suggests that those over 70 years old, who are at higher risk of serious illnesses and death from COVID-19, could build robust immunity
The COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against COVID-19.
They expect to release the late-stage trial results by December.
iRemedy Secures Factory Capacity for Needles and Syringes Required for Administration of COVID-19 Vaccinations.
The iRemedy Healthcare Company recently announced that they have procured factory capacity for the production of over one billion FDA-approved hypodermic needles and syringes that will be required for the administration of vaccinations.
iRemedy has already procured over 50 million units and has arranged for weekly deliveries from its factory partners through 2021. Current factory production cycles expect to result in the delivery of approximately 100 million units per month.
iRemedy is positioned to play a key supporting role in the distribution of the vaccines by providing needles, syringes, and related supplies.